Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
Author:
Affiliation:
1. Department of Internal Medicine Mayo Clinic Rochester Minnesota
2. Department of Oncology Mayo Clinic Rochester Minnesota
Publisher
Wiley
Subject
Oncology,Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21634
Reference144 articles.
1. Cancer statistics, 2020
2. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
3. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
4. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
5. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Cited by 98 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11
2. LncRNA ZNF649-AS1 promotes trastuzumab resistance and TAM-dependent PD-L1 expression in breast cancer by regulating EXOC7 alternative splicing;Archives of Biochemistry and Biophysics;2024-11
3. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10
4. Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer;Frontiers in Oncology;2024-08-15
5. PDL1/HER2‐Targeted Lipid‐Encapsulated Oxygen Nanobubbles Combined with Photodynamic Therapy for HER2+ Breast Cancer Immunotherapy;Advanced Healthcare Materials;2024-08-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3